ABBOTT LABORATORIES (ABT)       110.94  +0.39 (+0.35%)

2 Top Dividend Growth Stocks to Buy in February

They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.

FDA to overhaul food safety division in wake of baby formula issues (NYSE:ABT)

The US FDA will reorganize its food safety division to consolidate several functions in the aftermath of 2022's baby formula shortage to prevent a similar occurrence.

5 Top Stocks to Buy Now

This eclectic mix of stocks will help diversify your portfolio.

GE Healthcare Technology: Speculating On Dividends

GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one.

AbbVie’s global bestseller Humira to face knockoffs this week (NYSE:ABBV)

After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.

Is Abbott Laboratories a Good Dividend Stock to Buy Now?

At least four Wall Street banks recently raised their price targets for the healthcare giant.

Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review

Stocks reacted well to uneven earnings and economic reports.

Interesting ABT Put And Call Options For June 2024

Abbott recebe autorização da Anvisa para Ultreon™, tecnologia de imagem que usa inteligência artificial para artérias coronárias

O Software Ultreon™ 1.0, primeira tecnologia de imagem do gênero, mescla a tomografia de coerência óptica com o poder da automação usando inteligência...

Abbott wins FDA approval of Proclaim XR for diabetic peripheral neuropathy (NYSE:ABT)

The FDA has expanded the use of Abbott Laboratories' (ABT) Proclaim XR spinal cord stimulation system to include diabetic peripheral neuropathy.

Abbott's Sales and Earnings Are Sinking: Should Investors Worry?

There's more to the story than the negative trends for Abbott's top and bottom lines.

Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?

Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again.

Why Abbott Laboratories Stock Got Whacked on Wednesday

Double beats for its latest quarter couldn't keep the bears away from the company's shares on Hump Day.

Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript

ABT earnings call for the period ending December 31, 2022.

Why Aurora Cannabis Stock Is Fading Today

With discretionary spending under pressure, investors are shying away from this Canadian cannabis stock today.

Abbott Laboratories Skids As Covid Testing Weighs On Organic Growth

Overall sales topped forecasts, but organic growth missed expectations.

ABT stock falls as topline drops amid baby formula disruption (NYSE:ABT)

Despite a consensus beating Q4 2022, Abbott Laboratories (ABT) lost ~2% pre-market Wednesday as its revenue fell ~12% YoY amid disruption to baby formula production and waning COVID impact.

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022. Fourth-quarter sales of $10.1 billion, which...

Noteworthy Tuesday Option Activity: ACI, JOE, ABT

Abbott Q4 results in focus as DOJ probe on baby formula plant looms

Abbott Laboratories (ABT) is scheduled to announce Q4 earnings results on Wednesday, January 25th, before market open.The consensus EPS Estimate is $0.93 (-29.5% Y/Y) and the...

Want Safe and Growing Passive Income? Buy These 2 Dividend Kings In 2023

It doesn't get any safer for income investors than Dividend Kings.